Right time to take profit off the table in pharma ; defence a structural buy : Rajiv (...)
Rajiv Batra addresses global investors' concerns about India's growth and policy, emphasizing the need for double-digit earnings and nominal GDP growth to reignite foreign investor interest. He suggests profit-taking in pharma due to US generic concerns and underwhelming earnings. Batra remains (...)
Site référencé: The Economic Times
The Economic Times
Fitch affirms US credit at 'AA+', rising debt a ratings constraint
23/08/2025
Coal India, REC among top 10 largecap stocks with highest dividend yield in 1 year
23/08/2025
Fund Manager Talk | Ajay Khandelwal on India ⓐ 2047 : Markets, shifts, and opportunities ahead
23/08/2025
Sebi proposes CAS for derivative stocks to simplify pricing mechanism
23/08/2025
Sebi proposes changes to block deal framework to enhance market transparency
23/08/2025
Indian equities drop as investors book profits amid US tariff concerns
23/08/2025
